Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
November 2, 2023 - FOSTER CITY, Calif. & SANTA MONICA, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will share presentations, including oral presentations, during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (December 9-12).
Key presentations for Yescarta (axicabtagene ciloeleucel) in relapsed/refractory (R/R) large B-cell lymphoma (R/R LBCL) across lines of therapy include: three-year results from ZUMA-12 investigating CAR T-cell therapy as part of first-line treatment; ZUMA-7 overall survival sub-group analysis in patients aged 65+; and post-hoc analyses showing the curative intent of Yescarta using six-year follow-up data from ZUMA-1. Additional Yescarta research will focus on new four-year follow-up results from ZUMA-5 evaluating Yescarta in R/R indolent non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.
|
Oral Presentations |
||
|
Abstract Details |
Titles |
|
|
Large B-cell Lymphoma |
||
|
Abstract #103 Saturday, December 9, 2023 9:30 AM Room 6A |
Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (R/R LBCL) |
|
|
Abstract #894 Monday, December 11, 2023 4:00 PM Room 6A |
3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-cel) as First-Line Therapy in Patients with High-Risk Large B-cell Lymphoma (LBCL) |
|
|
Poster Presentations |
||
|
Large B-cell Lymphoma |
||
|
Abstract #1761 Saturday, December 9, 2023 5:30 - 7:30 PM Halls G-H |
Improved Overall Survival with Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Large B-cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7 |
|
|
Abstract #4864 Monday, December 11, 2023 6:00 - 8:00 PM Halls G-H |
Curative Potential of Axicabtagene Ciloleucel (Axi-cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-cell Lymphoma from ZUMA-1 | |
|
Mantle Cell, Follicular and Other Indolent B-Cell Lymphomas |
||
|
Abstract #2121 Saturday, December 9, 2023 5:30 - 7:30 PM Halls G-H |
Comparative Effectiveness of Axicabtagene Ciloleucel vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data |
|
|
Abstract #4868 Monday, December 11, 2023 6:00 - 8:00 PM Halls G-H |
Axicabtagene Ciloleucel (Axi-cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL): 4-Year Follow-up from the Phase 2 ZUMA-5 Trial |
|
|
Abstract #4869 Monday, December 11, 2023 6:00 - 8:00 PM Halls G-H |
An Updated Comparison of Clinical Outcomes from 4-year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) and the International SCHOLAR-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma |
|
|
Abstract #4865 Monday, December 11, 2023 6:00 - 8:00 PM Halls G-H |
A Retrospective Intra-Patient Analysis from ZUMA-5: Axicabtagene Ciloleucel (Axi-cel) Compared with Prior Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Follicular Lymphoma |
|
|
Multiple Myeloma |
||
|
Abstract #3383 Sunday, December 10, 2023 6:00 - 8:00 PM Halls G-H |
Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study |
|